Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids

Journal of Clinical Rheumatology

Volumn 17, Issue 1, 2011, Pages 23-27

  Bruck, Normi ^a   Suttorp, Meinolf ^a   Kabus, Maria ^b   Heubner, Georg ^a,c   Gahr, Manfred ^a   Pessler, Frank ^a,d  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b Department of Pediatrics   (Germany)

^c Department of Pediatrics   (United States)

^d HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

Macrophage activation syndrome; recombinant interleukin 1 antagonist; systemic juvenile idiopathic arthritis

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; IBUPROFEN; INDOMETACIN; INTERLEUKIN 1; METHYLPREDNISOLONE; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ARTICLE; CASE REPORT; CHILD; CORTICOSTEROID THERAPY; DRUG TOLERABILITY; FEMALE; FEVER; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HEPATOMEGALY; HUMAN; INCREASED APPETITE; INJECTION SITE PAIN; JUVENILE RHEUMATOID ARTHRITIS; MACROPHAGE ACTIVATION SYNDROME; MALE; PRIORITY JOURNAL; REMISSION; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; DEXAMETHASONE; DRUG TOLERANCE; FEMALE; GLUCOCORTICOIDS; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MACROPHAGE ACTIVATION SYNDROME; MALE; PREDNISOLONE; REMISSION INDUCTION;

EID: 78651365935     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e318205092d     Document Type: Article

References (12)

1. Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child. 2001;85:421-426.
2. Behrens EM, Beukelman T, Paessler M, et al. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol. 2007;34:1133-1138.
3. Cassidy JT, Petty RE. Textbook ofPediatric Rheumatology. 5th ed. Philadelphia, PA: Saunders; 2005.
4. Mouy R, Stephan JL, Pillet P, et al. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr. 1996;129:750-754.
5. Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124-131.
6. Makay B, Yilmaz S, Turkyilmaz Z, et al. Etanercept for therapy-resistant macrophage activation syndrome. Pediatr Blood Cancer. 2008;50:419-421.
7. Kelly A, Ramanan AV A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol. 2008;4:615-620.
8. Durand M, Troyanov Y, Laflamme P, et al. Macrophage activation syndrome treated with anakinra. J Rheum. 2010;37:879-880.
9. Cassidy JT, Levinson JE, Bass JC, et al. A study of classification criteria for a diagnosis of juvenile rheumatoid arthritis. Arthritis Rheum. 1986;29:274-281.
10. Ravelli A, Magni-Manzoni S, Pistorio A, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr. 2005;146:598-604.
11. Behrens EM, Kreiger PA, Cherian S, et al. Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis. J Rheumatol. 2006;33: 2081-2084.
12. Henter JI, Andersson B, Elinder G, et al. Elevated circulating levels of interleukin-1 receptor antagonist but not IL-1 agonists in hemophagocytic lymphohistiocytosis. Med Pediatr Oncol. 1996;27:21-25.